Notice for onasemnogene abeparvovec (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
onasemnogene abeparvovec
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Suspension for intravenous infusion
Indication
Treatment of patients with spinal muscular atrophy (SMA) with bi-allelic mutations in the SMN1 gene
Therapeutic area
Neurology